Adam Margolin, NextVivo CEO
Fledgling Stanford spinout promising 3D models of fully human tissue wins the backing of some big-time investors
When conducting preclinical tests in drug development, researchers have for years used different kinds of animal models, from mice to nonhuman primates. But what if the need for such models became obsolete?
It’s one of many questions hoping to be answered by the biotech NextVivo, which emerged from stealth Thursday morning with a small $7.9 million seed round. With prominent Silicon Valley VC Khosla Ventures as the lead, it’s clear NextVivo has, at the very least, tickled the minds of big-name investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
